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Abstract. : A series of robust iridium(I) complexes bearing a 
sterically encumbered N-heterocyclic carbene ligand, 
alongside a phosphine ligand, has been synthesised and 
investigated in hydrogen isotope exchange processes. These 
complexes have allowed isotope incorporation over a range 
of substrates with the use of practically convenient 
deuterium and tritium gas. Moreover, these active catalysts 
are capable of isotope incorporation to particularly high 
levels, whilst employing low catalyst loadings and in short 
reaction times. In addition to this, these new catalyst species 
have shown flexible levels of chemoselectivity, which can be 
altered by simple manipulation of preparative approaches.  
Furthermore, a number of industrially-relevant drug 
molecules have also been labelled, including the 
sulfonamide containing drug, Celecoxib. Alongside detailed 
NMR experiments, initial mechanistic investigations have 
also been performed, providing insight into both substrate 
binding energies, and, more importantly, relative energies 
of key steps in the mechanistic cycle as part of the overall 
exchange process. 
Keywords: hydrogen isotope exchange; iridium; catalysis; 
deuterium; tritium 
Introduction 
Despite colossal financial commitment to drug 
discovery, the pharmaceutical industry is burdened by 
unsustainable attrition rates associated with new 
chemical entities. Accordingly, positioning 
metabolism and pharmacokinetic studies earlier in 
such discovery programmes is crucial in assessing the 
overall properties of a drug candidate and as aligned 
to reducing the present levels of attrition of over 
90%.[1] One key methodology applied extensively 
within this area is isotopic labelling, which allows the 
biological fate of a potential drug molecule to be 
carefully monitored.[2] In particular, transition metal-
catalysed hydrogen isotope exchange (HIE) offers a 
simple and direct technique, which potentially allows 
the regioselective labelling of fully functionalised 
molecules (Scheme 1), eliminating the need for any 
additional synthetic processes or prolonged 
preparative pathways associated with the installation 
of an isotopic label. 
Whilst various transition metal species have 
demonstrated activity within the field of HIE,[3-6] for a 
QXPEHU RI \HDUV &UDEWUHH¶V FDWDO\VW
[Ir(COD)(PCy3)(py)]PF6,
[7] was regarded as the 
industry standard to facilitate such a process. This 
iridium-based complex demonstrates appreciable 
 
 
Scheme 1. Ideal hydrogen isotope exchange process. 
activity in the labelling of a range of substrates, 
however, it is often found that (super-)stoichiometric 
quantities of the catalyst and lengthy reaction times 
are required to deliver the observed levels of isotope 
incorporation.[8] In addition, tritiation reactions 
SURPRWHG E\ &UDEWUHH¶V FDWDO\VW IUHTXently produce 
considerable quantities of radioactive waste, which is 
a clear drawback with regards to both cost and 
environmental concerns.[2c,9] In view of the issues 
DVVRFLDWHGZLWK&UDEWUHH¶V FDWDO\VW LW LV HYLGHQW WKDW
alternative metal-based complexes for use in 
hydrogen isotope exchange would be beneficial to 
pharmaceutical partners with, in particular, the 
desired catalysts being capable of labelling an 
assortment of substrates to high levels of 
incorporation under mild reaction conditions and with 
lowered catalyst loadings. Following the work of 
Nolan[10] and Buriak[11] in the field of olefin 
hydrogenation, we felt that in order to enhance 
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catalytic activity in HIE processes, relative to 
&UDEWUHH¶VFDWDO\VWJUHDWHUVWHULFGHPDQGDURXQGWKH
metal centre, coupled with balanced electronic 
parameters, was required.[12] In this regard, we have 
reported on the preparation and application of a series 
of new iridium complexes bearing a bulky N-
heterocyclic carbene (NHC), 1,3-bis(2,4,6-
trimethylphenyl)imidazol-2-ylidene (IMes), alongside 
an appreciably encumbered phosphine, and which 
have appreciable potential as highly active catalysts 
for HIE with deuterium.[13] Additionally, we have 
shown that these robust and practically accessible 
iridium species can be applied within the selective 
reduction of alkenes (and alkynes)[14] and in the Z-
selective dimerization of terminal alkynes.[15] 
 Herein, we report the activity and selectivity 
spectrum of this class of iridium complex in the area 
of deuterium and, importantly, tritium labelling, as 
well as our initial investigations into the overall 
mechanism of the hydrogen isotope exchange process 
with these emerging catalyst species. 
Results and Discussion 
First of all, and importantly in a practical sense, a 
robust and readily utilisable route to our novel Ir(I) 
complexes bearing a sterically encumbered NHC in 
conjunction with a bulky tertiary phosphine ligand 
was achieved according to a variation of a procedure 
delineated by Herrmann.[16] The use of sodium 
ethoxide in the relatively weakly coordinating solvent, 
benzene, was crucial to allow the in situ generation 
and introduction of the NHC ligand, avoiding the 
necessity to pre-form and isolate the free carbene 
species under glovebox conditions. Following this 
modified synthetic route, five novel Ir(I) complexes 
were delivered in good yields (Table 1). These bright 
red catalysts are air- and moisture-stable crystalline 
solids, and have been characterised by NMR and 
mass spectral techniques. In addition, the structures 
of complex 5a-c have been confirmed by X-ray 
crystallography.[13a]  
Table 1. Preparation of iridium complexes.a)  
 
Entry PR3 Complex Yield
b) 
1 PPh3 5a 62 
2 PBn3 5b 59 
3 PMe2Ph 5c 71 
4 PMePh2 5d 69 
5 P(OiPr)3 5e 75 
a) Reaction conditions: (a) NaOEt, PhH, r.t., 10 min. (b) 4, 
PhH, r.t., 5 h. (c) AgPF6, THF, r.t., 30 min. (d) PR3, THF, 
r.t., 2 h. b) Isolated yields. 
Under the standard reaction conditions developed 
within our laboratory, employing a catalyst loading of 
5 mol% in DCM under 1 atmosphere of D2 gas for 16 
h, complexes 5a-e facilitated high levels of H/D 
exchange across a wide range of substrates (6a-i) 
including ketones, amides, and heterocyclic 
functionalities (Table 2). In general, compounds 7a-g, 
which are labelled via a 5-membered metallocyclic 
intermediate (5-mmi), were delivered with high 
deuterium incorporations in a regioselective and 
reproducible manner. Furthermore, the isotopic 
labelling of weakly coordinating nitrobenzene, 6g, 
proceeded without incident and with no reduction of 
the nitro moiety, as has been detected with previously 
employed catalysts.[5f,8b] It is important to highlight 
that the levels of isotope exchange in benzamide, 6c, 
were somewhat more variable, ranging from 32% in 
the presence of complex 5a, to 90% in reactions 
catalysed by complex 5d. Indeed, this substrate is 
notoriously difficult to label effectively, with 110 
PRORI&UDEWUHH¶VFDWDO\VWEHLQJSUHYLRXVO\ 
Table 2. HIE studies with complexes 5a-e.a),b) 
 
 
 
 
a) 5 mol% of Ir catalyst employed over 16 h. b) Average 
incorporation into the positions shown over two separate 
reaction runs; the percentage given refers to the level of D 
incorporation over the total number of positions shown, e.g. 
97% for the two possible positions in 7a indicates 1.94 D 
incorporation. 
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required to deliver the isotopically-enriched product 
with only a moderate 65% D incorporation.[8b] The 
examination of additional substrates revealed the 
ability of our novel Ir(I) complexes to also facilitate 
isotope exchange in C-H bonds positioned five bonds 
away from the required coordinating functionality i.e. 
via a 6-membered metallocyclic intermediate (6-
mmi). This process is believed to be energetically 
more demanding and, as such, often leads to lower 
levels of deuteration. In our hands, the simplest 
substrate of this class, acetanilide, 6h, was labelled up 
to an excellent 95% D loading. Furthermore, 
deuterium incorporation in benzanilide, 6i, occurred 
with high degrees of exchange observed in positions 
labelled via both a 5-mmi and a 6-mmi. 
To further explore the capabilities of our 
complexes, a series of rate and activity studies were 
performed. A loading study revealed that excellent 
deuterium incorporation is maintained in the presence 
of catalyst quantities as low as 0.5 mol% (Scheme 2). 
Furthermore, whereas catalyst 5a mediated the 97% 
deuteration of 6a within 120 minutes, more electron-
rich catalysts, 5b and 5c, delivered more rapid 
labelling (60 and 90 minutes, respectively). 
Presumably, the more electron-rich catalysts better 
facilitate the C-H activation process central to the 
H/D exchange reaction.[17] 
 
 
Scheme 2. Catalyst loading and labelling time study. 
The excellent levels of efficiency displayed by 
these complexes prompted us to examine their 
catalytic activity further. As demonstrated in the 
labelling of 6i (Table 2), benzanilide substrates offer 
two potential sites of labelling, through either a 5- or 
6-mmi. It was therefore proposed that the emerging 
catalysts had the potential to exert regioselective 
deuteration in substrates of this type. Such 
discrimination of H/D exchange in one position over 
another would be of particular benefit to 
pharmaceutical partners, allowing specific drug 
metabolites to be traced preferentially during in vivo 
distribution studies. In an attempt to establish such 
selective HIE, the labelling of benzanilide 6j was 
studied. As illustrated in Scheme 3, the use of 5 
mol% of complex 5c delivered appreciably high 
levels of isotope incorporation in both positions a and 
b. In contrast, reducing the amount of catalyst present 
in the reaction system to 0.5 mol% resulted in a 
significant decline in the degree of labelling observed 
in position b, via a 6-mmi, while the elevated level of 
exchange in position a, proceeding via the more 
favourable 5-mmi, was maintained. A similar result 
was obtained with the benzanilide derivative 6k, 
which is capable of labelling through both a 5- and a 
6-mmi at three possible sites in the molecule. At a 5 
mol% catalyst loading, complex 5c showed excellent 
levels of incorporation into positions a and b (both 
via a 5-mmi), while position c (via a 6-mmi) showed 
more moderate D uptake. Pleasingly, when the 
catalyst loading was reduced to 0.5 mol%, not only 
did we again observe exclusive labelling via the 5-
mmi over the 6-mmi, there was also selectivity noted 
between positions a and b. The preferential labelling 
at position a suggests more effective iridium metal 
centre coordination with the more available oxygen 
lone pairs within the amide carbonyl group over the 
oxygen atoms of the nitro unit. 
 
 
Scheme 3. Labelling selectivity for a 5-mmi over a 6-mmi. 
 Based on these findings, it was envisaged that 
our overall protocols could be manipulated to achieve 
selective labeling into a position labelled via a 6-mmi 
(Scheme 4). This was accomplished by employing 
the heavily labelled compound 7j (a: 96%; b; 93%) as 
substrate with H2 to allow H exchange at position a, 
leaving the deuterium in place at position b. As 
shown in Scheme 4, employing 5 mol% of complex 
5c under an atmosphere of hydrogen resulted in the 
selective removal of deuterium via the 5-mmi, while 
the level of D at position b remained high. 
Accordingly, this section of our study has shown that 
it is now possible to access both classes of selectively 
labelled compounds, which illustrates a further 
distinct practical advantage delivered by these novel 
iridium catalyst systems. To our knowledge, this level 
of labelling selectivity by this direct approach is 
unprecedented in the literature. 
 
 
Scheme 4. Selective removal of the D Label via the 5-mmi. 
To further illustrate the capabilities of these 
catalysts, a number of available drug molecules were 
applied in hydrogen isotope exchange reactions. The 
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ability to label fully functionalised drug scaffolds is 
central to the application of HIE catalysis, especially 
as aligned to the endeavours of pharmaceutical 
partners. Pleasingly, complexes 5a-c performed very 
well with a series of drug substrates at relatively low 
catalyst loadings and over short reaction times (7l-o; 
Table 3). Of particular note is the high level of D 
incorporation in the Pfizer COX-2 inhibitor, 
Celecoxib, 7m. In addition to the high level of D 
uptake obtained in position b, the D incorporation at 
position a represents the first example of deuterium 
labelling adjacent to a primary sulfonamide moiety as 
facilitated by complexes of this type,[18] albeit at 
relatively moderate levels. Furthermore, Sanofi-
$YHQWLV¶ DQWL-androgen Nilutamide, 7n, provides a 
further example of preferential labelling via a 5-mmi 
over a 6-mmi. 
Table 3. HIE studies with marketed drug molecule 
substrates. 
 
a) 5 mol% of Ir catalyst employed over 16 h. b) 10 mol% of 
Ir catalyst employed over 1 h. c) 2.5 mol% of Ir catalyst 
employed over 1 h. d) 5 mol% of Ir catalyst employed over 
1 h. 
Following the exploration of substrate scope, we 
sought to gain further insight regarding the 
effectiveness of our novel system via the analysis of 
catalyst turnover. As shown in Table 4, the 
deuteration of acetophenone using catalyst 5b 
delivered very good turnover within a 6 h reaction 
period, using extremely low levels of catalyst. Under 
WKH VDPH FRQGLWLRQV &UDEWUHH¶V FDWDO\VW VKRZHG D
vastly reduced efficiency; presumably due to its 
lower relative activity and instability over time.[12] 
Mechanistic Investigations 
Although the mechanism of iridium-catalysed HIE 
was proposed by Heys in 1996,[5d] there exists only 
Table 4. Catalyst turnover. 
 
Entry L1/L2 
(catalyst) 
% D TONa) TOFb) 
1 IMes/PBn3 
(5b) 
88 1056 176 
2 Py/Ph3P &UDEWUHH¶V 
29 348 58 
a) Measured as no. moles of substrate converted/no. moles 
of catalyst employed. b) Measured as no. moles of substrate 
converted/no. moles of catalyst employed/hours. 
limited evidence to support the perceived sequence of 
events.[5o] Therefore, we were interested in embarking 
upon focused mechanistic investigations to increase 
the general comprehension of such catalysed 
hydrogen isotope exchange process. Further, by 
embedding our emerging iridium complex class 
within this study, we envisaged that any enhanced 
understanding could provide beneficial foundations to 
be used in the design of future catalyst systems. 
 Initially and to this end, an exchange reaction 
was carried out in an NMR tube, using deuterated 
dichloromethane, to allow us to monitor two key 
features in the proposed pathway: the initial removal 
of the cyclooctadiene (COD) unit from the iridium 
complex, and the resultant geometry of the major 
ligands around the metal centre. Since the formation 
of iridium hydrides is thought to be central to the 
removal of the COD ligand, the reverse exchange 
reaction (Scheme 5) was carried out by employing 
fully deuterated acetophenone 9 and exchanging with 
hydrogen gas, in an attempt to observe any potential 
Ir-hydride species. Complex 5a was chosen as this is 
the slowest acting of this series of catalysts, with 10 
mol% being employed in order to fully observe 
intermediate complexes and reaction progression by 
NMR analysis (see Supporting Information for full 
details). 
 
 
Scheme 5. Reverse exchange reaction monitored in an 
NMR tube. 
Prior to the monitoring of the reaction, it was 
necessary to gather data on the parent complex, to 
allow the detection of any changes that occur as the 
overall process progresses. Accordingly, 1H and 31P 
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NMR spectra of complex 5a were obtained in CD2Cl2. 
The most relevant 1H spectrum peaks at the beginning 
of the reaction were the multiplets at 4.39-4.36 and 
3.35-3.33 ppm, as shown in Figure 1. These peaks 
correspond to the olefinic protons of the COD ligand, 
and are expected to lose intensity and disappear at the 
beginning of the reaction as the COD is reduced. 
With regards to the 31P NMR, the peak present at 
16.35 ppm corresponds to the phosphine ligand 
bound to the metal centre. 
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Figure 1. 1H (top) and 31P (bottom) NMR spectra of 
complex 5a in CD2Cl2. 
 Figure 2 shows a 2D 31P/13C HMQC experiment 
of the same parent complex 5a. This allowed the 2JPC 
coupling constant between the bound phosphorus 
atom and the carbon of the carbene ligand to be 
established. It was envisaged that by carrying out this 
correlation experiment as the reaction proceeds, the 
observed magnitude of this 2JPC coupling constant 
would provide some indication of the geometry of the 
two major ligands. As presented in Figure 2, a 
distinct correlation was observed between the bound 
phosphine at 16.35 ppm and the carbene carbon at 
177 ppm. The 2JPC coupling constant was measured at 
8.6 Hz, in accord with these two ligands adopting a 
cis-arrangement in the parent complex. In turn, we 
were confident that the geometry of the ligands in any 
reaction intermediates could then be deduced by 
comparing the coupling constants obtained 
throughout the reaction. Consequently, the reaction 
(Scheme 5) was performed in an NMR tube using d5-
acetophenone 9 and hydrogen gas, with CD2Cl2 as the 
reaction solvent. Following the initial addition of 
hydrogen gas, several peaks emerged in the 1H NMR 
spectrum in the region of -13-0 ppm, indicating the 
presence of the expected iridium hydrides. The 
reaction was then further monitored to assess the 
reduction and removal of the COD ligand, as shown 
by the disappearance of the multiplet peaks at 4.39-
4.36 and 3.35-3.33 ppm; importantly, following this 
further analysis the peaks corresponding to the 
iridium hydrides had also disappeared, suggesting 
that these hydrides play a key role in the removal of 
the COD ligand. Furthermore, in the absence of the 
COD ligand, 31P NMR analysis showed that the 
original phosphine signal (16.35 ppm) had been 
replaced with a new peak at 20.80 ppm, indicating 
that the parent complex had been fully converted to 
an alternative phosphorus-containing iridium species 
within the reaction manifold. 
 
 
Figure 2. 2D 31P/13C HMQC experiment of the parent 
complex. 
 To further investigate the new COD-free iridium 
intermediate, a second 2D HMQC 13C/31P correlation 
spectrum was obtained. As illustrated in Figure 3, the 
carbene carbon signal at 177 ppm had been replaced 
by a new signal at ~160 ppm. This change in 
chemical shift was accompanied by a correlation to 
the phosphine signal at 20.80 ppm, and with an 
appreciably elevated 2JPC coupling constant of 118 Hz. 
Indeed, such large 2JPC coupling constants in similar 
iridium complexes, bearing phosphine and NHC 
ligands, have some literature precedent. For example, 
iridium(I) complex 11, depicted in Figure 4, has been 
shown to have the triphenylphosphine and bis-benzyl 
NHC ligands in a relative trans-arrangement.[19a] The 
data for this compound reveal the carbene carbon of 
the NHC to have a chemical shift of 177.6 ppm and a 
2
JPC coupling constant of 116 Hz. In an analogous 
manner, iridium(III) complex 12 has the tri-iso-
propylphosphine and IMes ligands in a trans-
configuration, with a similar 2JPC coupling constant 
value of 108 Hz.[19b] However, the chemical shift of 
the carbene carbon in this latter complex is 
significantly more upfield than that of complex 11, 
with a value of 165 ppm. From the evidence obtained 
regarding the activated catalytic species in our HIE 
reaction, and from comparison with available 
literature data,[19] it is proposed that the intermediate 
within this manifold has the phosphine and NHC 
ligands in a trans geometry; further, the 13C NMR 
chemical shift of the carbene carbon is consistent 
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with this new catalytic intermediate possessing an 
iridium(III) oxidation state.  
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Figure 3. 2D 31P/13C HMQC spectrum of intermediate Ir 
complex. 
 
Figure 4. Known Ir complexes with phosphine/NHC 
ligands in a trans-arrangement. 
To further support the above experimental 
evidence that the phosphine and NHC ligands align 
themselves in a trans-configuration, density 
functional theory (DFT) studies (see Supporting 
Information for full details on the level of theory 
used) were employed to calculate the relative 
energies of the proposed cis- and trans-isomers of the 
intermediate iridium species. Using +H\V¶
mechanism as a guide,[5d] the most sterically hindered 
species along the catalytic cycle is envisaged to be 
that formed subsequent to oxidative insertion with the 
substrate, e.g. 13 with acetophenone (Figure 5). 
Therefore, the energetic ordering of the possible 
isomers of 13 was investigated to determine the 
probable active configuration within the HIE 
manifold. 
 
 
Figure 5. Oxidative addition intermediate in the catalytic 
cycle. 
Potential orientations of the D2, hydride, and 
substrate ligands were investigated; however, all 
alternative configurations converged to one of the 
three isomers shown in Figure 6. In addition to the 
trans-isomer 13, two cis-isomers were also optimised 
to local minima on the potential energy surface (14 
and 15, Figure 6). The relative energies of the three 
isomers indicate that 14 and 15 are destabilised by 
8.83 and 10.12  kcal/mol, respectively, relative to 13. 
These findings support the experimental evidence 
that the phosphine and NHC adopt a trans-orientation 
within the activated Ir species. 
 
 
Figure 6. Optimised structures of 13 and its isomers at 
DFT level. 
Our DFT calculations were further expanded to 
focus on the possible reaction pathway by which 
hydrogen isotope exchange proceeds. These more 
detailed investigations allowed the construction of the  
potential energy surface (PES) associated with the 
proposed catalytic cycle. Using that suggested by 
Heys as a basis,[5d] a mechanistic pathway employing 
our Ir(I) complexes in conjunction with acetophenone, 
6a, was determined (Scheme 6). It is proposed that, 
following exposure to deuterium gas, complex 5a 
loses the COD ligand as d4-cyclooctane. The 
resulting coordinately unsaturated Ir species is 
stabilised by coordination of the substrate, e.g. 6a, 
delivering 16. Following oxidative addition to give 
13, fluxionality of the dihydrogen hydride (ĺ) 
allows isotopic hydrogen to orient in the position cis 
to the Ir-C bond, resulting, ultimately, in reductive 
elimination (ĺ) and isotope incorporation into 
the ortho-position of the substrate aryl ring, D¶. In 
UHODWLRQ WR PRGLILFDWLRQV WR +H\V¶ RULJLQDO
mechanistic scheme, we now believe that the initial 
activated iridium species is stabilised by association 
of the substrate forming complex 16 in which the 
ortho aryl C-H is agostically coordinated to the 
iridium centre. Furthermore and in a more general 
sense, a series of 31P NMR magnetization transfer 
experiments, analogRXV WR WKH ZRUN RI *UXEEV¶
within the field of ruthenium-catalysed olefin 
metathesis,[20] indicate that the phosphine ligand does 
not dissociate from the iridium metal centre 
throughout the catalytic cycle (see Supporting 
Information for experimental details). 
All of the intermediates and transition states 
involved in our proposed catalytic cycle, with the 
incorporation of deuterium, have been fully optimised. 
Therefore, the enthalpy changes during the reaction 
progress have been monitored. Relative enthalpies of 
the stationary points on the PES and the barriers to 
oxidative addition, H/D exchange, and reductive 
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Scheme 6. Proposed HIE catalytic cycle. 
elimination have also been calculated for each species 
shown in Scheme 6. In addition to the use of PPh3 
and in order to probe the possibility of performing 
computational studies of more minimised cost, PMe3 
was also investigated as the axial phosphine ligand 
(Table 5). The decreased ligand size in the PMe3 
systems does not alter the mechanism of the reaction, 
nor does it strongly affect the geometry of the ligands 
around the equatorial plane, i.e. there is no large 
rearrangement of the ligands and the changes in bond 
lengths between the full (PPh3) systems and the 
trimmed (PMe3) version are calculated to be in the 
region of 0.02 Å (see Supporting Information for 
details). Comparing the calculated energetic 
parameters detected along the reaction path for both 
PPh3 and PMe3 (Table 5), the axial phosphine 
substituent has a detectable impact on the energy of 
the oxidative addition step, with a difference of 1.43 
kcal/mol calculated for TS(16-13) between the 
species bearing PPh3 and the smaller PMe3. 
 With regards to the key steps in our proposed 
catalytic cycle and considering the PPh3 system, the 
oxidative addition of the iridium into the aryl C-H 
bond, requires a moderate activation enthalpy of 
16.70 kcal/mol (Table 5, Figure 7). Further, the 
conversion of 16 to 13 is endothermic by 3.66 
kcal/mol with respect to 16. The subsequent H/D 
exchange step ( ĺ ) is calculated to be rapid, 
with an activation barrier of 2.25 kcal/mol. In 
contrast to oxidative insertion, reductive elimination 
is favoured enthalpically, presumably due to the 
decrease in steric strain within the vicinity of the 
metal centre. Accordingly and based on this 
calculated PES, we can conclude that the rate-
limiting step within such H/D exchange processes 
appears to involve the oxidative addition or reductive 
elimination of the ortho-C-H bonds. In a 
complementary experimental study, we strengthened 
this argument by observing a primary kinetic isotope 
effect of approximately 3.7 (see Supporting 
Information for full details). This suggests that C-H 
activation[21] is, indeed, rate-limiting.  
 Having established the relative reaction 
energetics in HIE reactions employing acetophenone, 
6a, attention turned to the reactivity of our catalysts 
with respect to different target molecules. Such 
studies also offered the potential to explain the 
selective labelling of substrates via a 5-mmi as 
opposed to a 6-mmi. Three substrates were selected 
for investigation: acetophenone, 6a, 2-phenylpyridine, 
6e, and acetanilide, 6h (Figure 8). 
 In view of the similar energy values calculated 
for complexes bearing either PPh3 or PMe3 as the 
axial ligand, the remaining theoretical studies were 
performed with the smaller tertiary phosphine ligand 
in place. As our previous explorations had supported 
C-H activation as being rate determining, the effects 
of the alternative substrates were examined within 
this portion of the catalytic process (Table 6). As  
Table 5. 5HODWLYHHQHUJLHV¨(HQWKDOSLHV¨+DQG*LEEVIUHHHQHUJLHV¨*IRUWKHFDWDO\WLFF\FOHFDOFXODWHGDW')7
level (all are in kcal/mol). 
 
Species 
¨Ea) ¨Hb) ¨Gb) 
PPh3 PMe3 PPh3 PMe3 PPh3 PMe3 
16 0.00 0.00 0.00 0.00 0.00 0.00 
TS(16-13) 17.21 18.14 16.70 18.13 18.65 18.35 
13 3.33 0.93 3.66 1.20 2.88 0.27 
TS(13-17) 5.86 3.17 5.91 3.66 5.05 2.10 
17 3.43 0.93 3.75 1.19 3.00 0.30 
TS(17-18) 17.39 18.39 16.94 18.35 18.50 18.62 
18 -0.42 -0.44 -0.45 -0.48 -0.41 -0.42 
a) Energies are zero-point corrected. b) All enthalpies and Gibbs free energies are at 298.15K. 
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Figure 7. The reaction PES employing Ph3P as the phosphine ligand. 
 
Figure 8. Substrates used in the DFT calculations. 
revealed by the activation enthalpy values the 
substrates labelling via a 5-mmi, acetophenone, 6a, 
and 2-phenylpyridine, 6e, were found to be most 
active. The identification of acetanilide, 6h, as the 
least active substrate further supports our more 
general observations that compounds which are 
labelled via a 6-mmi are less reactive in our catalysed 
HIE reactions (vide supra).[5d] 
Table 6. Enthalpy changes for the oxidative addition step 
with three different substrates. 
 
Species 
¨Ha),b) 
6a
 
6e
 
6h
 
16 0.00 0.00 0.00 
TS(16-13) 18.13 17.53 23.04 
13 1.20 2.73 5.11 
a) All enthalpy changes are in kcal/mol at 298.15 K. b) 
Calculations are based on the catalyst bearing the smaller 
PMe3 ligand.
 
Further theoretical calculations were performed to 
determine the binding energies of the three substrates 
under investigation (Table 7), since these had 
previously also been shown to influence labelling 
efficiencies.[22] 7KH VWDELOLVDWLRQ HQHUJ\ ¨+bind, 
resulting from the complexation of the substrate to 
the iridium metal, forming the species akin to 16, is 
calculated as the difference in enthalpy between the 
enthalpy of the optimised complex, 16, and the sum 
of the enthalpies of the optimised substrate and the 
optimised [(D2)Ir(PMe3)(NHC)]
+ complex. As 
illustrated by the values in Table 7, all complexes 
have a stabilising interaction enthalpy with the 
substrates. It should be noted that the values 
presented represent binding enthalpies, as opposed to 
free energies, and, as such, entropic effects have not 
been accounted for. In all cases, the entropic 
contribution will negatively affect the stability of the 
complex relative to the separated reactants. 
As shown in Table 7, substrate 6e binds most 
strongly to the iridium centre compared to other 
substrates, presumably due to the better binding 
ability of the more basic N atom, relative to a 
carbonyl O atom. In addition, substrate 6h binds to 
the iridium centre with a similar strength as displayed 
by substrate 6a. In both cases the coordination 
proceeds via interaction of the oxygen atom lone pair 
of electrons to the metal core. Hence, it can be 
deduced that the activation enthalpy, rather than the 
binding enthalpy, dictates the more effective labelling 
via a 5- over a 6-mmi. 
Table 7. Calculated binding energies (PR3 = PMe3). 
Substrate 6a 6e 6h 
¨Hbinda) -23.48 -31.42 -23.94 
a) All relative enthalpies are in kcal/mol at 298.15 K. 
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Incorporation of Tritium 
Following the success of our emerging iridium 
phosphine/carbene species for H/D exchange, and 
with an improved understanding of the catalytic 
mechanism, investigations were undertaken to 
ascertain whether these Ir species could also facilitate 
hydrogen-tritium exchange reactions. Since 
radionuclides can be detected more sensitively than 
stable isotopes, it is common practice within 
pharmaceutical laboratories to prepare both the stable 
isotopically-labelled molecule and the radio-labelled 
compound.[2c,9] Therefore, it was important to 
determine the activity of the developed catalysts in 
the labelling of substrates with tritium. Due to the 
more challenging hydrogen-tritium exchange process, 
based on the increased tritium-tritium bond strength, 
5 mol% catalyst loading was required. Nonetheless, 
over a relatively short reaction time of only 2 hours, a 
successful tritiation protocol was achieved (Table 8). 
Table 8. Tritiation studies with catalysts 5a-c.a),b) 
 
a) 5 mol% of Ir catalyst employed over 2 hours. b) Tx 
(where x = 0, 1, 2, 3, 4) refers to the number of tritium 
atoms incorporated into the molecule, e.g. for 19b, T1 (23) 
indicates that 23% of the sample contained one tritium 
atom. See Supporting Information for further details. 
Tritiation via a 5-mmi proved relatively facile with 
high levels of T uptake being observed (19b, 19e, 
19p). Perhaps as anticipated, hydrogen-tritium 
exchange through a 6-mmi was less efficient, with 
only 7% incorporation achieved with acetanilide, 19h.  
As anticipated, only the position activated through 
the 5-mmi in 19j was labelled regioselectively and 
with good levels of effectiveness. Of particular note 
was the extremely successful tritiation of the drug 
molecule Celecoxib, 19m; further and in contrast 
with the analogous deuterium experiment, only the 
positions ortho to the pyrazole directing group 
displayed tritium incorporation. With respect to all 
examples shown in Table 8, we were pleased to note 
that the process was remarkably clean, with no 
significant tritiated by-products being observed. 
Indeed, in previous studies we have revealed an 
appreciably different reaction profile, possessing an 
array of T-possessing by-SURGXFWV ZKHQ &UDEWUHH¶V
catalyst is employed.[9] 
Conclusions 
By embedding a bulky N-heterocyclic carbene ligand 
in combination with different phosphine ligands, a 
series of highly active iridium-based catalysts have 
been developed for hydrogen isotope exchange. Such 
catalysts have been shown to produce high 
incorporations of deuterium and tritium adjacent to a 
good range of relevant functional units within a series 
of compounds, including pharmaceutically-active 
agents. Additionally, combined experimental and 
computational studies have led to a deeper 
understanding of the nature of such catalyst systems 
and the active species generated, as well the overall 
reaction mechanism. These investigations have 
indicated that the C-H activation process is the rate-
limiting step within this HIE manifold. Further, the 
C-H activation event also constitutes the 
regiochemistry-determining step when both 5- and 6-
metallocyclic intermediates are possible, leading to 
appreciable selectivities within the established 
exchange processes. 
 With regards the pivotal C-H activation, we 
believe that the electron-rich ligand set employed as 
part of the emerging catalyst systems is central to the 
facilitation of the requisite oxidative addition step 
within the catalytic cycle. Further, the sterically 
crowded ligand sphere will, in turn, aid reductive 
elimination. In relation to this latter point, when 
sterically less demanding phosphine/NHC 
combinations were applied within our laboratory, the 
resulting complexes displayed appreciably lowered 
activity within HIE processes. It should also be noted 
that the bulky NHC and phosphine ligands used 
within our series of iridium complexes could provide 
the active catalytic species, formed within the 
reaction manifold, with enhanced levels of stability 
by preventing the existence of inactive iridium 
clusters[12] or driving the presence of monomeric 
active iridium species.[11b] 
 Overall, the novel catalysts developed for HIE 
reactions within this programme have the clear 
SRWHQWLDOWRUHSODFH&UDEWUHH¶VFDWDO\VWDVWKHLQGXVWU\
standard in this area. Moreover, these complexes are 
stable in air and at room temperature, retaining their 
activity over prolonged storage periods. The 
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experimental and computational methods employed 
here, aligned with the associated mechanistic and 
theoretical insights delivered through this study, are 
now being employed within our laboratory in 
endeavours to develop catalyst systems of further 
enhanced activity and more widespread substrate 
applicability. 
Computational Methods 
Density functional theory (DFT) was employed to 
calculate the electronic structures and energies for all 
species involved in H/D exchange reactions. A hybrid 
meta-GGA exchange correlation functional M06[23] 
was used in conjunction with the 6-31G(d,p)[24] basis 
set for main group non-metal atoms and the Stuttgart 
RSC[25] effective core potential along with the 
associated basis set for Ir. Harmonic vibrational 
frequencies are calculated (with the incorporation of 
deuterium wherever needed) at the same level of 
theory to characterise respective minima (reactants, 
intermediates, and products with no imaginary 
frequency) and first order saddle points (TSs with one 
imaginary frequency). All calculations have been 
performed with the GAUSSIAN 09 quantum 
chemistry programme package. More detailed 
discussion of the computational methods, with full 
references, can be found in the Supporting 
Information. 
Experimental Section 
General Procedure for the Synthesis of Complexes 5a-
5e: 
A flame dried and nitrogen cooled Schlenk tube was 
charged with 3 and dry benzene  
(10 mL). The solution was treated with freshly prepared 1 
M sodium ethoxide solution and stirred for 10 minutes. 
After this time, 4 was added and the mixture stirred for 5 h 
at r.t. The solvent was removed under high vacuum and the 
residue triturated with dry ether prior to filtration through 
celite under N2. After solvent exchange to dry THF (15 
mL), AgPF6 was added and the resultant slurry stirred for 
30 minutes at r.t. After filtration through celite under N2, 
the solution was treated with phosphine and the resultant 
ruby red solution was stirred for 2 h. Purification by 
recrystallisation yielded the desired complex. 
Standard Hydrogen Isotope Exchange Procedure: 
A flame dried and nitrogen cooled 250 mL 3-neck round 
bottomed flask, equipped with two stopcock valves and a 
suba seal, was charged with the iridium complex (5 mol%) 
and dry DCM (2.5 mL), followed by the substrate (0.215 
mmol). The suba seal was replaced with a greased glass 
stopper and the reaction vessel was cooled to -78 qC in a 
dry ice/acetone bath, prior to being purged twice with 
nitrogen. The flask was then evacuated and filled with 
deuterium gas via balloon. The flask was removed from 
the slurry and allowed to warm to room temperature. 
(NOTE: the glass stopper must be physically restrained as 
the reaction mixture warms to room temperature; further 
standard caution should also be observed ensuring the 
robust nature of the glassware used and the employment of 
less vigorous stirring at this stage in the process). The 
reaction mixture was then allowed to stir vigorously at 
room temperature for the allotted reaction time. After this 
time, excess deuterium gas was removed from the system 
under vacuum. The reaction mixture was concentrated 
under reduced pressure and the catalyst complex was 
precipitated using diethyl ether (~10 mL) and removed by 
filtration through a plug of silica. Concentration of the 
filtrate under reduced pressure yielded the 
product/substrate mixture, which was analysed by 1H 
NMR spectroscopy. The level of isotope incorporation into 
the substrate was determined by 1H NMR analysis of the 
reaction products. As such, the residual proton signal from 
the site of incorporation was compared against that of a 
site where incorporation was not expected or occurred. 
Full details of all experimental procedures, analyses, and 
DFT calculations (including optimised Cartesian 
coordinates) can be found in the Supporting Information.  
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